Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults

Last updated: December 4, 2024
Sponsor: University of Washington
Overall Status: Completed

Phase

N/A

Condition

Aging

Treatment

STOP Falls Educational Intervention

Clinical Study ID

NCT05689554
SITE00000971
CD002967
  • Ages > 60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The overall objective of STOP-FALLS is to test whether a patient-centered deprescribing intervention that focuses on CNS-active medications reduces medically treated falls among older adults. The aims are: AIM 1: Adapt and pilot-test an evidence-based medication reduction intervention for use in an integrated health care system. AIM 2: Implement and evaluate the adapted intervention using a cluster-randomized controlled trial design. Aim 3: Assess barriers and facilitators to intervention implementation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • For opioid and sedative-hypnotic medications, eligible participants are aged 60years or older, while for skeletal muscle relaxants, tricyclic antidepressants, andfirst-generation antihistamines, eligible participants are aged 65 years or older.

Eligible participants must be long-term users of the target medication, defined as pharmacy dispensing of at least one of the target medication classes for at least 70 of the prior 90 days.

Further, eligible participants must either be assigned to a primary care provider (PCP) or have had 1+ visits in the prior year with a PCP at one of the 18 Kaiser Permanente Washington clinics participating in the study.

Exclusion

Exclusion Criteria:

  1. diagnosis of dementia or a prescription for a medication used to treat dementia (i.e., a cholinesterase inhibitor or memantine);

  2. residence in a skilled nursing facility;

  3. metastatic cancer diagnosis in the prior 12 months;

  4. receiving hospice or palliative care;

  5. legally blind (unable to read print materials);

  6. indication the participant requires a translator (cannot read materials printed inEnglish); g) enrolled in other KPWA opioid deprescribing research studies;

h) enrolled in a KPWA pharmacy-driven initiative to reduce opioid doses; or i) diagnosed with opioid use disorder

Study Design

Total Participants: 2367
Treatment Group(s): 1
Primary Treatment: STOP Falls Educational Intervention
Phase:
Study Start date:
April 01, 2021
Estimated Completion Date:
September 30, 2023

Study Description

Background: Central nervous system (CNS) active medications have been consistently linked to falls in older people. However, few randomized trials have evaluated whether CNS-active medication reduction reduces falls and fall-related injuries. The objective of the Reducing CNS-active Medications to Prevent Falls and Injuries in Older Adults (STOP-FALLS) trial is to test the effectiveness of a health-system-embedded deprescribing intervention focused on CNS-active medications on the incidence of medically treated falls among community-dwelling older adults.

This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial within Kaiser Permanente Washington to test the effectiveness of a 12-month deprescribing intervention consisting of: 1) an educational brochure and self-care handouts mailed to older adults prescribed one or more CNS-active medications (aged 60+: opioids, benzodiazepines and Z-drugs; aged 65+: skeletal muscle relaxants, tricyclic antidepressants, and antihistamines) and 2) decision support for their primary health care providers. Outcomes are examined over 18-26 months post-intervention. The primary outcome is first incident (post-baseline) medically treated fall as determined from health plan data. Sample size calculations ensured at least 80% power to detect a 20% reduction in the rate of medically treated falls for participants receiving care within the intervention (n=9) versus usual care clinics (n=9) assuming 18 months of follow-up. Secondary outcomes include medication discontinuation or dose reduction of any target medications. Safety outcomes include serious adverse drug withdrawal events, unintentional overdose, and death. The study team will also examine medication signetur fields for attempts to decrease medications. The study team will report factors affecting implementation of the intervention.

Connect with a study center

  • Kaiser Permanente Washington Health Research Institute

    Seattle, Washington 98101
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.